<DOC>
	<DOCNO>NCT00927589</DOCNO>
	<brief_summary>This Phase Ib , multicenter , single-arm , open-label study design evaluate effect trastuzumab QTcF interval characterize effect trastuzumab carboplatin pharmacokinetics patient HER2-positive metastatic locally advanced inoperable cancer . The QT interval measure time start Q wave end T wave heart 's electrical cycle . The QTcF interval QT interval calculate use Fridericia 's correction ; QTcB interval QT interval calculate use Bazett 's correction .</brief_summary>
	<brief_title>A Study Evaluate Corrected QT Interval Drug-Drug Interaction Trastuzumab Carboplatin Presence Docetaxel Patients With HER2-Positive Metastatic Locally Advanced Inoperable Cancer</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologic documentation HER2positive solid malignancy patient metastatic locally advanced inoperable disease Left ventricular ejection fraction ( LVEF ) &gt; /= 50 % multiplegated acquisition ( MUGA ) scan twodimensional echocardiography ( ECHO ) &lt; /= 42 day prior Cycle 1 , Day 1 History trastuzumab treatment &lt; /= 100 day prior Cycle 1 , Day 1 Pretreatment QTcF interval &gt; 450 m determine local assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HER2+ Metastatic Cancer</keyword>
	<keyword>HER2+ Locally Advanced Inoperable Cancer</keyword>
	<keyword>HER2+ Solid Malignancy</keyword>
</DOC>